(-0.01%) 5 477.75 points
(-0.04%) 38 803 points
(0.03%) 19 927 points
(0.29%) $80.56
(1.18%) $2.82
(0.14%) $2 332.20
(-0.31%) $29.30
(-0.13%) $969.60
(0.02%) $0.932
(-0.12%) $10.64
(0.09%) $0.788
(-1.87%) $86.80
Live Chart Being Loaded With Signals
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States...
Stats | |
---|---|
Šios dienos apimtis | 161 295 |
Vidutinė apimtis | 16 665 |
Rinkos kapitalizacija | 42.63M |
EPS | $-0.270 ( Q1 | 2024-05-15 ) |
Kita pelno data | ( $-0.430 ) 2024-08-12 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-3.46 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0800 (1.67%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-06-30 | Lurier Eliot M | Buy | 0 | |
2021-03-16 | Eansor Norman David | Buy | 14 285 | Common Stock |
2023-06-06 | Eansor Norman David | Buy | 8 000 | Stock Option (right to buy) |
2021-03-25 | Eansor Norman David | Buy | 7 142 | Common Stock |
2021-03-25 | Eansor Norman David | Sell | 14 285 | Common Stock |
INSIDER POWER |
---|
100.00 |
Last 91 transactions |
Buy: 66 397 235 | Sell: 1 245 536 |
Marker Therapeutics Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Marker Therapeutics Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $3.31M |
Bruto pelnas: | $-7.11M (-214.60 %) |
EPS: | $-1.930 |
FY | 2023 |
Pajamos: | $3.31M |
Bruto pelnas: | $-7.11M (-214.60 %) |
EPS: | $-1.930 |
FY | 2022 |
Pajamos: | $9.00M |
Bruto pelnas: | $5.32M (59.13 %) |
EPS: | $-3.58 |
FY | 2021 |
Pajamos: | $1 242.00 |
Bruto pelnas: | $1 241.71 (100.00 %) |
EPS: | $-8.90 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Marker Therapeutics Inc
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.